SlideShare ist ein Scribd-Unternehmen logo
1 von 25
Downloaden Sie, um offline zu lesen
PRESENTED BY : SANDEEP BANSAL
CLASS : M.PHARMACY 1st year
(DRA)
ROLL NO.180000802004
Pharmaceutical and medical device agency (PMDA).
Organization of PMDA.
Pharmaceutical laws and regulations.
Drug master file system in Japan.
Drug regulatory approval procedure in Japan.
IND and NDA applications.
Post marketing surveillance in Japan.
Japan cosmetic regulations.
 PMDA (Pharmaceuticals and Medical Devices Agency) is
Japanese regulatory agency, working together with Ministry of
health and labour welfare (MHLW).
 The PMDA was established in April 2004 in order to serve in
areas of review of drugs and medical devices, post-marketing
safety measures, relief services for adverse health effects.
 Our obligation is to protect the public health by assuring
safety, efficacy and quality of pharmaceuticals and medical
devices.
 The role of the PMDA is to provide consultations concerning
the clinical trials of new drugs and medical devices, and to
conduct approval reviews and surveys of the reliability of
application data.
◦ Drug and medical device testing:
◦ Scientific review of market authorization applications based
on Japanese pharmaceutical law.
◦ Advice in clinical trials or in the preparation of dossiers for
the registration procedure (New Drug Applications (NDA).
◦ Inspection and conformity assessment of Good Clinical
Practice (GCP), Good Laboratory Practice (GLP), and Good
Practice Systems and Programs (GPSP)
◦ Auditing of manufacturers to ensure they conform to Good
Manufacturing Practice(GMP) and have a suitable Quality
Management System(QMS).
 It consists of the ministry proper, affiliated institutions,
councils, local branches, and external organizations.
 The ministry proper includes the Minister's Secretariat, 11
bureaus, and the Director-General for Policy Planning and
Evaluation.
 Councils include the Social Insurance Council, Pharmaceutical
Affairs and Food Sanitation Council (PAFSC), and other
organizations.
 Affiliated institutions include the National Institute of Health
Sciences and the National Institute of Infectious Diseases.
 Local branches are regional bureaus of health and welfare and
prefectural labor bureaus. The external organizations are the
Social Insurance Agency and the Central Labor Relations
Commission.
Regulatory requirnment and approval procedure of drugs in japan ppt
 Pharmaceutical administration in Japan is based on
various laws and regulations, consisting mainly of:
1. The Drugs and Medical Devices Law,
2. Law Concerning the Establishment for
Pharmaceuticals and Medical Devices Organization,
3. Law Concerning Securing Stable Supply of Blood
Products,
4. Poisonous and Deleterious Substances Control Law
5. Narcotics and Psychotropic Control Law
6. Cannabis Control Law,
7. Opium Law, and
8. Stimulants Control Law.
 A DMF is a system to register confidential data on quality,
manufacturing methods, etc. of a drug substance used for a
drug. Domestic and foreign drug manufacturers register their
DMFs to the PMDA on a voluntary basis.
 The manufacturer of the drug substance can be reviewed by
the competent Japanese authority without sharing information
containing details on its manufacturing methods, production
management and quality control with the manufacturers of the
drug product.
 DMF is reviewed at the time of the approval review for the
pharmaceutical products quoting DMF. At the time of DMF
registration, PMDA checks whether it is written in the correct
format, e.g., minimum required items are included
(application) and data is attached (CTD M3).
 The entire process of approval review from review-
related inspections and clinical trial consultation to
review works is undertaken by the PMDA.
 Application forms for approval to market drugs are
usually submitted to the PMDA.
 When application forms for new drugs are received
by the PMDA, a compliance review of the
application data (certification from source data), GCP
on-site inspection, and detailed review are undertaken
by review teams of the PMDA and the team prepares
a review report.
 Application form (written).
 Application letter (XML).
 Protocols.
 Case report form.
 IB ( investigator brochure).
 Written reason with appropriate request for clinical
trials.
◦ IND application to be prepared in the common
technical document format (CTD) format.
◦ Pre-IND meeting.
◦ Subsequent to the application submission, PMDA
evaluates the application with respect to the preclinical
data and protocols for clinical studies etc.
◦ It may probably take 30 days for initial IND and 14
days for second IND.
◦ After PMDA completes the review, the IND fill will be
transferred to the IRB board for the review.
◦ IRB takes 1-4 weeks of time for the complete review.
◦ Once IRB approved the review than the clinical trials
on human beings will be started.
Regulatory requirnment and approval procedure of drugs in japan ppt
 The entire process of approval review from review-
related inspections and clinical trial consultation to
review works is undertaken by the PMDA.
 Application forms for drug marketing authorization
are submitted to the PMDA.
 When application forms for new drug s marketing
authorization are received by the PMDA, a
compliance review of the application data
(certification from source data), GCP on-site
inspection, and detailed review are undertaken by
review teams of the PMDA and the team prepares a
review report.
 The approval review process consists of expert meetings
of review team members and experts to discuss important
problems.
 A general review conference attended by team members,
experts and representatives of the applicant is held after
the expert meeting.
 It is necessary to submit a “list of persons involved in
compilation of attached data” and a “list of competitive
products and companies” in relation to persons who
participated in clinical studies submitted as application
data immediately after application submission, prior to the
expert meeting, and prior to meeting of the Committee on
Drugs.
Regulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan ppt
◦ Post-marketing surveillance (PMS) to assure the quality,
efficacy and safety of drugs after they go on the market and
to establish proper methods of use of drugs consists of three
systems: the ADRs and infections collection and reporting
system, the re examination system, and the revaluation
system.
◦ The re-examination system for new drugs was introduced in
the October 1979 amendment of the Pharmaceutical Affairs
Law, and Good Post-marketing Surveillance Practice
(GPMSP) came into effect from April 1993 to assure proper
implementation of PMS and also to assure the reliability of
such PMS data.
Regulatory requirnment and approval procedure of drugs in japan ppt
◦ Cosmetic products in Japan are regulated by Ministry of
Health, Labour and Welfare (MHLW) under the
Pharmaceutical and Medical Devices Law (PMDL, formerly
Pharmaceutical Affairs Law). According to PMDL, beauty
products are divided into cosmetics and quasi-drugs and
regulation differs greatly between cosmetics and quasi-
drugs.
◦ Cosmetics refer to articles with mild action on the human
body, which are intended to be applied to the human body
through rubbing, sprinkling or other methods, aiming to
clean, beautify and increase the attractiveness, alter the
appearance or to keep the skin or hair in good condition.
◦ Before obtaining license of marketing or importation,
manufacturers/importers of cosmetics shall submit 2
notifications to the competent authority:
 Cosmetic marketing notification
 Cosmetics (foreign manufacturer, importer) notification.
 The two notifications must either be accompanied by a list of
full ingredients from the importer’s supplier or manufacturer
or, if this list cannot be obtained, a record of the testing and
inspection results confirming the product does not contain any
prohibited ingredient combinations instead.
Regulatory requirnment and approval procedure of drugs in japan ppt
 Pharmaceuticals and Medical Devices Agency [Internet]. Pmda.go.jp. 2019
[cited 27 April 2019]. Available from: https://www.pmda.go.jp/english/.
 Pharmaceuticals and Medical Devices Agency, Japan - drug approval
[Internet]. Ss.pmda.go.jp. 2019 [cited 27April 2019]. Available from:
https://ss.pmda.go.jp/en_all/search.x?q=drug+approval&ie=utf8&cat=0&p
agemax=10&imgsize=1&pdf=ok&zoom=1&suggest=1&counsel=1&ref=w
ww.pmda.go.jp&pid=cGCqvKFAypc38kBls6lHVg..&qid=XWa44tkTt9qK
BO6nc1TrrEXm9Eg3J02D&d=Drugs.
 Organization | Pharmaceuticals and Medical Devices Agency [Internet].
Pmda.go.jp. 2019 [cited 27April 2019]. Available from:
https://www.pmda.go.jp/english/about-pmda/outline/0003.html.
 Guidance on Drug Master File System in Japan [Internet]. Pmda.go.jp.
2019 [cited 27 April 2019]. Available from:
https://www.pmda.go.jp/files/000227208.pdf.
 Master File System | Pharmaceuticals and Medical Devices Agency [Internet].
Pmda.go.jp. 2019 [cited 27 April 2019]. Available from:
https://www.pmda.go.jp/english/review-services/reviews/mf/0001.html.
 Drug Approval System of Japan - Google Search [Internet]. Google.com. 2019
[cited 27 April 2019]. Available from:
https://www.google.com/search?rlz=1C1RLNS_enIN743IN743&ei=RibFXJ1
NbS0mgfnioLoAQ&q=Drug+Approval+System+of+Japan&oq=Drug+Approv
al+System+of+Japan&gs_l=psyab.3..0i22i30j0i333l3.67937.70585..71559...1.
0..4.584.1596.0j2j3j5-1....3..0....1j2..gws-wiz.....6..0i71j35i39.4hjcWErlAYc.
 POST-MARKETING SAFETY MEASURES IN JAPAN [Internet].
Pmda.go.jp. 2019 [cited 27 April 2019]. Available from:
https://www.pmda.go.jp/files/000152319.pdf.
 The Regulation of Cosmetics in Japan [Internet]. Yakujihou.com. 2019
[cited 28 April 2019]. Available from:
http://www.yakujihou.com/img/CosRegulationJapan.pdf.
Regulatory requirnment and approval procedure of drugs in japan ppt

Weitere ähnliche Inhalte

Was ist angesagt?

Electronic submission PPT
Electronic submission PPTElectronic submission PPT
Electronic submission PPTDoninder Hooda
 
MEDICAL DEVICE APPROVAL PROCESS IN JAPAN
MEDICAL DEVICE APPROVAL PROCESS IN JAPANMEDICAL DEVICE APPROVAL PROCESS IN JAPAN
MEDICAL DEVICE APPROVAL PROCESS IN JAPANDeveshDRA
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Aakashdeep Raval
 
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...Swapnil Fernandes
 
Good Automated Laboratory Practices
Good Automated Laboratory PracticesGood Automated Laboratory Practices
Good Automated Laboratory PracticesSwapnil Fernandes
 
Organizaton chart of us fda.
Organizaton chart of us fda.Organizaton chart of us fda.
Organizaton chart of us fda.Rovil Goel
 
Regulatory authority of japan
Regulatory authority of japanRegulatory authority of japan
Regulatory authority of japanAadityaThole
 
Regulatory requirement and approval procedure for medical devices
Regulatory requirement and approval procedure for medical devicesRegulatory requirement and approval procedure for medical devices
Regulatory requirement and approval procedure for medical devicesAtul Bhombe
 
Market authorisation checklist for brics countries
Market authorisation checklist for brics countriesMarket authorisation checklist for brics countries
Market authorisation checklist for brics countriesJAYA PRAKASH VELUCHURI
 
Medical devices and IVD'S
Medical devices and IVD'SMedical devices and IVD'S
Medical devices and IVD'SSanthiNori1
 
Who prequalification program
Who prequalification programWho prequalification program
Who prequalification programshweta more
 
Regulation of medical device in japan
Regulation of medical device in japanRegulation of medical device in japan
Regulation of medical device in japanKrushnaAgnihotri
 
European_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptxEuropean_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptxNikhilBorade5
 
Clinical Research Regulation in European Union
Clinical Research Regulation in European Union Clinical Research Regulation in European Union
Clinical Research Regulation in European Union ShantanuThakre3
 
GOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICEGOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICEjagrutivasava
 

Was ist angesagt? (20)

Electronic submission PPT
Electronic submission PPTElectronic submission PPT
Electronic submission PPT
 
MEDICAL DEVICE APPROVAL PROCESS IN JAPAN
MEDICAL DEVICE APPROVAL PROCESS IN JAPANMEDICAL DEVICE APPROVAL PROCESS IN JAPAN
MEDICAL DEVICE APPROVAL PROCESS IN JAPAN
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.
 
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
 
Good Automated Laboratory Practices
Good Automated Laboratory PracticesGood Automated Laboratory Practices
Good Automated Laboratory Practices
 
GHTF study group 3
GHTF study group 3GHTF study group 3
GHTF study group 3
 
Ghtf study group 4
Ghtf study group 4Ghtf study group 4
Ghtf study group 4
 
Organizaton chart of us fda.
Organizaton chart of us fda.Organizaton chart of us fda.
Organizaton chart of us fda.
 
Regulatory authority of japan
Regulatory authority of japanRegulatory authority of japan
Regulatory authority of japan
 
Regulatory requirement and approval procedure for medical devices
Regulatory requirement and approval procedure for medical devicesRegulatory requirement and approval procedure for medical devices
Regulatory requirement and approval procedure for medical devices
 
ACTD- ASEAN
ACTD- ASEANACTD- ASEAN
ACTD- ASEAN
 
Market authorisation checklist for brics countries
Market authorisation checklist for brics countriesMarket authorisation checklist for brics countries
Market authorisation checklist for brics countries
 
Medical devices and IVD'S
Medical devices and IVD'SMedical devices and IVD'S
Medical devices and IVD'S
 
Doc in pharma
Doc in pharmaDoc in pharma
Doc in pharma
 
Who prequalification program
Who prequalification programWho prequalification program
Who prequalification program
 
Regulation of medical device in japan
Regulation of medical device in japanRegulation of medical device in japan
Regulation of medical device in japan
 
European_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptxEuropean_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptx
 
Clinical Research Regulation in European Union
Clinical Research Regulation in European Union Clinical Research Regulation in European Union
Clinical Research Regulation in European Union
 
Medical Device Regulations - 510(k) Process
Medical Device Regulations - 510(k) ProcessMedical Device Regulations - 510(k) Process
Medical Device Regulations - 510(k) Process
 
GOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICEGOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICE
 

Ähnlich wie Regulatory requirnment and approval procedure of drugs in japan ppt

Japan drug and cosmetics regulation.pdf
 Japan drug and cosmetics  regulation.pdf Japan drug and cosmetics  regulation.pdf
Japan drug and cosmetics regulation.pdfBhavikaAPatel
 
To compare filing process of NDA of different countries of India, US and Euro...
To compare filing process of NDA of different countries of India, US and Euro...To compare filing process of NDA of different countries of India, US and Euro...
To compare filing process of NDA of different countries of India, US and Euro...Aakashdeep Raval
 
Central Drugs Standard Control Organization (CDSCO).pdf
Central Drugs Standard Control Organization (CDSCO).pdfCentral Drugs Standard Control Organization (CDSCO).pdf
Central Drugs Standard Control Organization (CDSCO).pdfDr. Archana. S. N
 
4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdfASSAM DOWN TOWN UNIVERSITY
 
Regulations of medical devices in india
Regulations of medical devices in indiaRegulations of medical devices in india
Regulations of medical devices in indiasuspandanachowdary
 
IND, NDA, ANDA, SNDA
IND, NDA, ANDA, SNDAIND, NDA, ANDA, SNDA
IND, NDA, ANDA, SNDAMANIKANDAN V
 
REGULATORY CONSIDERATIONS IN JAPAN.pptx
REGULATORY CONSIDERATIONS IN JAPAN.pptxREGULATORY CONSIDERATIONS IN JAPAN.pptx
REGULATORY CONSIDERATIONS IN JAPAN.pptxAartiVats5
 
rashmi presentation
rashmi presentationrashmi presentation
rashmi presentationRASHMINasare
 
Pharmacovigilance sytem in United States of America (USA)
Pharmacovigilance sytem in United States of America (USA)Pharmacovigilance sytem in United States of America (USA)
Pharmacovigilance sytem in United States of America (USA)PharmXL International Pvt. Ltd.
 
Regulatory Authorities for Pharmaceuticals - TGA,MHRA,MCC
Regulatory Authorities for Pharmaceuticals - TGA,MHRA,MCCRegulatory Authorities for Pharmaceuticals - TGA,MHRA,MCC
Regulatory Authorities for Pharmaceuticals - TGA,MHRA,MCCSanket Shinde
 
regulatory affairs ip ii final
regulatory affairs  ip ii finalregulatory affairs  ip ii final
regulatory affairs ip ii finalAudumbar Mali
 
Oncology Drugs: The journey From Manufacturer To The End User
Oncology Drugs: The journey From Manufacturer To The End UserOncology Drugs: The journey From Manufacturer To The End User
Oncology Drugs: The journey From Manufacturer To The End UserPharmacy @ Institut Kanser Negara
 
Drug regulatory affairs - 1
Drug regulatory affairs - 1Drug regulatory affairs - 1
Drug regulatory affairs - 1Tanuja Bisht
 

Ähnlich wie Regulatory requirnment and approval procedure of drugs in japan ppt (20)

Japan drug and cosmetics regulation.pdf
 Japan drug and cosmetics  regulation.pdf Japan drug and cosmetics  regulation.pdf
Japan drug and cosmetics regulation.pdf
 
radc.pptx
radc.pptxradc.pptx
radc.pptx
 
To compare filing process of NDA of different countries of India, US and Euro...
To compare filing process of NDA of different countries of India, US and Euro...To compare filing process of NDA of different countries of India, US and Euro...
To compare filing process of NDA of different countries of India, US and Euro...
 
Drug Regulatory Affairs (DRA)
Drug Regulatory Affairs (DRA)Drug Regulatory Affairs (DRA)
Drug Regulatory Affairs (DRA)
 
Pharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh Alemi
Pharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh AlemiPharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh Alemi
Pharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh Alemi
 
Central Drugs Standard Control Organization (CDSCO).pdf
Central Drugs Standard Control Organization (CDSCO).pdfCentral Drugs Standard Control Organization (CDSCO).pdf
Central Drugs Standard Control Organization (CDSCO).pdf
 
4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf
 
Regulations of medical devices in india
Regulations of medical devices in indiaRegulations of medical devices in india
Regulations of medical devices in india
 
Regulatory affairs
Regulatory affairsRegulatory affairs
Regulatory affairs
 
DRUG REGULATORY AFFAIRS
DRUG REGULATORY AFFAIRS DRUG REGULATORY AFFAIRS
DRUG REGULATORY AFFAIRS
 
IND, NDA, ANDA, SNDA
IND, NDA, ANDA, SNDAIND, NDA, ANDA, SNDA
IND, NDA, ANDA, SNDA
 
Cdsco ppt
Cdsco pptCdsco ppt
Cdsco ppt
 
REGULATORY CONSIDERATIONS IN JAPAN.pptx
REGULATORY CONSIDERATIONS IN JAPAN.pptxREGULATORY CONSIDERATIONS IN JAPAN.pptx
REGULATORY CONSIDERATIONS IN JAPAN.pptx
 
rashmi presentation
rashmi presentationrashmi presentation
rashmi presentation
 
Pharmacovigilance sytem in United States of America (USA)
Pharmacovigilance sytem in United States of America (USA)Pharmacovigilance sytem in United States of America (USA)
Pharmacovigilance sytem in United States of America (USA)
 
Regulatory Authorities for Pharmaceuticals - TGA,MHRA,MCC
Regulatory Authorities for Pharmaceuticals - TGA,MHRA,MCCRegulatory Authorities for Pharmaceuticals - TGA,MHRA,MCC
Regulatory Authorities for Pharmaceuticals - TGA,MHRA,MCC
 
regulatory affairs ip ii final
regulatory affairs  ip ii finalregulatory affairs  ip ii final
regulatory affairs ip ii final
 
Oncology Drugs: The journey From Manufacturer To The End User
Oncology Drugs: The journey From Manufacturer To The End UserOncology Drugs: The journey From Manufacturer To The End User
Oncology Drugs: The journey From Manufacturer To The End User
 
Drug regulatory affairs - 1
Drug regulatory affairs - 1Drug regulatory affairs - 1
Drug regulatory affairs - 1
 
Drug Regulatory Affairs
Drug Regulatory AffairsDrug Regulatory Affairs
Drug Regulatory Affairs
 

Mehr von sandeep bansal

ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA sandeep bansal
 
Comparative study of drug approval system in usa, europe & japan
Comparative study of drug approval system in usa, europe & japanComparative study of drug approval system in usa, europe & japan
Comparative study of drug approval system in usa, europe & japansandeep bansal
 
Regulatory approval and system of drug master file ,IND and NDA in USA
Regulatory approval and system of  drug master file ,IND  and NDA in USARegulatory approval and system of  drug master file ,IND  and NDA in USA
Regulatory approval and system of drug master file ,IND and NDA in USAsandeep bansal
 
regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...sandeep bansal
 
Pharmaceutical Dossier submission
 Pharmaceutical Dossier submission Pharmaceutical Dossier submission
Pharmaceutical Dossier submissionsandeep bansal
 
Content and format of dossier filling in india
Content and format of dossier filling in india Content and format of dossier filling in india
Content and format of dossier filling in india sandeep bansal
 
World health organisation
World health organisation World health organisation
World health organisation sandeep bansal
 
Presentation on cancer
Presentation on cancerPresentation on cancer
Presentation on cancersandeep bansal
 

Mehr von sandeep bansal (8)

ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
 
Comparative study of drug approval system in usa, europe & japan
Comparative study of drug approval system in usa, europe & japanComparative study of drug approval system in usa, europe & japan
Comparative study of drug approval system in usa, europe & japan
 
Regulatory approval and system of drug master file ,IND and NDA in USA
Regulatory approval and system of  drug master file ,IND  and NDA in USARegulatory approval and system of  drug master file ,IND  and NDA in USA
Regulatory approval and system of drug master file ,IND and NDA in USA
 
regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...
 
Pharmaceutical Dossier submission
 Pharmaceutical Dossier submission Pharmaceutical Dossier submission
Pharmaceutical Dossier submission
 
Content and format of dossier filling in india
Content and format of dossier filling in india Content and format of dossier filling in india
Content and format of dossier filling in india
 
World health organisation
World health organisation World health organisation
World health organisation
 
Presentation on cancer
Presentation on cancerPresentation on cancer
Presentation on cancer
 

Kürzlich hochgeladen

EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 

Kürzlich hochgeladen (20)

EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 

Regulatory requirnment and approval procedure of drugs in japan ppt

  • 1. PRESENTED BY : SANDEEP BANSAL CLASS : M.PHARMACY 1st year (DRA) ROLL NO.180000802004
  • 2. Pharmaceutical and medical device agency (PMDA). Organization of PMDA. Pharmaceutical laws and regulations. Drug master file system in Japan. Drug regulatory approval procedure in Japan. IND and NDA applications. Post marketing surveillance in Japan. Japan cosmetic regulations.
  • 3.  PMDA (Pharmaceuticals and Medical Devices Agency) is Japanese regulatory agency, working together with Ministry of health and labour welfare (MHLW).  The PMDA was established in April 2004 in order to serve in areas of review of drugs and medical devices, post-marketing safety measures, relief services for adverse health effects.  Our obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices.  The role of the PMDA is to provide consultations concerning the clinical trials of new drugs and medical devices, and to conduct approval reviews and surveys of the reliability of application data.
  • 4. ◦ Drug and medical device testing: ◦ Scientific review of market authorization applications based on Japanese pharmaceutical law. ◦ Advice in clinical trials or in the preparation of dossiers for the registration procedure (New Drug Applications (NDA). ◦ Inspection and conformity assessment of Good Clinical Practice (GCP), Good Laboratory Practice (GLP), and Good Practice Systems and Programs (GPSP) ◦ Auditing of manufacturers to ensure they conform to Good Manufacturing Practice(GMP) and have a suitable Quality Management System(QMS).
  • 5.  It consists of the ministry proper, affiliated institutions, councils, local branches, and external organizations.  The ministry proper includes the Minister's Secretariat, 11 bureaus, and the Director-General for Policy Planning and Evaluation.  Councils include the Social Insurance Council, Pharmaceutical Affairs and Food Sanitation Council (PAFSC), and other organizations.  Affiliated institutions include the National Institute of Health Sciences and the National Institute of Infectious Diseases.  Local branches are regional bureaus of health and welfare and prefectural labor bureaus. The external organizations are the Social Insurance Agency and the Central Labor Relations Commission.
  • 7.  Pharmaceutical administration in Japan is based on various laws and regulations, consisting mainly of: 1. The Drugs and Medical Devices Law, 2. Law Concerning the Establishment for Pharmaceuticals and Medical Devices Organization, 3. Law Concerning Securing Stable Supply of Blood Products, 4. Poisonous and Deleterious Substances Control Law 5. Narcotics and Psychotropic Control Law 6. Cannabis Control Law, 7. Opium Law, and 8. Stimulants Control Law.
  • 8.  A DMF is a system to register confidential data on quality, manufacturing methods, etc. of a drug substance used for a drug. Domestic and foreign drug manufacturers register their DMFs to the PMDA on a voluntary basis.  The manufacturer of the drug substance can be reviewed by the competent Japanese authority without sharing information containing details on its manufacturing methods, production management and quality control with the manufacturers of the drug product.  DMF is reviewed at the time of the approval review for the pharmaceutical products quoting DMF. At the time of DMF registration, PMDA checks whether it is written in the correct format, e.g., minimum required items are included (application) and data is attached (CTD M3).
  • 9.  The entire process of approval review from review- related inspections and clinical trial consultation to review works is undertaken by the PMDA.  Application forms for approval to market drugs are usually submitted to the PMDA.  When application forms for new drugs are received by the PMDA, a compliance review of the application data (certification from source data), GCP on-site inspection, and detailed review are undertaken by review teams of the PMDA and the team prepares a review report.
  • 10.  Application form (written).  Application letter (XML).  Protocols.  Case report form.  IB ( investigator brochure).  Written reason with appropriate request for clinical trials.
  • 11. ◦ IND application to be prepared in the common technical document format (CTD) format. ◦ Pre-IND meeting. ◦ Subsequent to the application submission, PMDA evaluates the application with respect to the preclinical data and protocols for clinical studies etc. ◦ It may probably take 30 days for initial IND and 14 days for second IND. ◦ After PMDA completes the review, the IND fill will be transferred to the IRB board for the review. ◦ IRB takes 1-4 weeks of time for the complete review. ◦ Once IRB approved the review than the clinical trials on human beings will be started.
  • 13.  The entire process of approval review from review- related inspections and clinical trial consultation to review works is undertaken by the PMDA.  Application forms for drug marketing authorization are submitted to the PMDA.  When application forms for new drug s marketing authorization are received by the PMDA, a compliance review of the application data (certification from source data), GCP on-site inspection, and detailed review are undertaken by review teams of the PMDA and the team prepares a review report.
  • 14.  The approval review process consists of expert meetings of review team members and experts to discuss important problems.  A general review conference attended by team members, experts and representatives of the applicant is held after the expert meeting.  It is necessary to submit a “list of persons involved in compilation of attached data” and a “list of competitive products and companies” in relation to persons who participated in clinical studies submitted as application data immediately after application submission, prior to the expert meeting, and prior to meeting of the Committee on Drugs.
  • 18. ◦ Post-marketing surveillance (PMS) to assure the quality, efficacy and safety of drugs after they go on the market and to establish proper methods of use of drugs consists of three systems: the ADRs and infections collection and reporting system, the re examination system, and the revaluation system. ◦ The re-examination system for new drugs was introduced in the October 1979 amendment of the Pharmaceutical Affairs Law, and Good Post-marketing Surveillance Practice (GPMSP) came into effect from April 1993 to assure proper implementation of PMS and also to assure the reliability of such PMS data.
  • 20. ◦ Cosmetic products in Japan are regulated by Ministry of Health, Labour and Welfare (MHLW) under the Pharmaceutical and Medical Devices Law (PMDL, formerly Pharmaceutical Affairs Law). According to PMDL, beauty products are divided into cosmetics and quasi-drugs and regulation differs greatly between cosmetics and quasi- drugs. ◦ Cosmetics refer to articles with mild action on the human body, which are intended to be applied to the human body through rubbing, sprinkling or other methods, aiming to clean, beautify and increase the attractiveness, alter the appearance or to keep the skin or hair in good condition.
  • 21. ◦ Before obtaining license of marketing or importation, manufacturers/importers of cosmetics shall submit 2 notifications to the competent authority:  Cosmetic marketing notification  Cosmetics (foreign manufacturer, importer) notification.  The two notifications must either be accompanied by a list of full ingredients from the importer’s supplier or manufacturer or, if this list cannot be obtained, a record of the testing and inspection results confirming the product does not contain any prohibited ingredient combinations instead.
  • 23.  Pharmaceuticals and Medical Devices Agency [Internet]. Pmda.go.jp. 2019 [cited 27 April 2019]. Available from: https://www.pmda.go.jp/english/.  Pharmaceuticals and Medical Devices Agency, Japan - drug approval [Internet]. Ss.pmda.go.jp. 2019 [cited 27April 2019]. Available from: https://ss.pmda.go.jp/en_all/search.x?q=drug+approval&ie=utf8&cat=0&p agemax=10&imgsize=1&pdf=ok&zoom=1&suggest=1&counsel=1&ref=w ww.pmda.go.jp&pid=cGCqvKFAypc38kBls6lHVg..&qid=XWa44tkTt9qK BO6nc1TrrEXm9Eg3J02D&d=Drugs.  Organization | Pharmaceuticals and Medical Devices Agency [Internet]. Pmda.go.jp. 2019 [cited 27April 2019]. Available from: https://www.pmda.go.jp/english/about-pmda/outline/0003.html.  Guidance on Drug Master File System in Japan [Internet]. Pmda.go.jp. 2019 [cited 27 April 2019]. Available from: https://www.pmda.go.jp/files/000227208.pdf.
  • 24.  Master File System | Pharmaceuticals and Medical Devices Agency [Internet]. Pmda.go.jp. 2019 [cited 27 April 2019]. Available from: https://www.pmda.go.jp/english/review-services/reviews/mf/0001.html.  Drug Approval System of Japan - Google Search [Internet]. Google.com. 2019 [cited 27 April 2019]. Available from: https://www.google.com/search?rlz=1C1RLNS_enIN743IN743&ei=RibFXJ1 NbS0mgfnioLoAQ&q=Drug+Approval+System+of+Japan&oq=Drug+Approv al+System+of+Japan&gs_l=psyab.3..0i22i30j0i333l3.67937.70585..71559...1. 0..4.584.1596.0j2j3j5-1....3..0....1j2..gws-wiz.....6..0i71j35i39.4hjcWErlAYc.  POST-MARKETING SAFETY MEASURES IN JAPAN [Internet]. Pmda.go.jp. 2019 [cited 27 April 2019]. Available from: https://www.pmda.go.jp/files/000152319.pdf.  The Regulation of Cosmetics in Japan [Internet]. Yakujihou.com. 2019 [cited 28 April 2019]. Available from: http://www.yakujihou.com/img/CosRegulationJapan.pdf.